1. Introduction
Skin grafts are commonly used by physicians to promote healing and skin closure in nonhealing wounds, such as chronic and burn wounds [
1,
2]. There are several types of grafts that can be chosen, such as autografts (skin grafts obtained from the patient themselves), allografts (obtained from human donors), and xenografts (obtained from other species) [
1]. Autografts are the standard treatment for definitive chronic wound closure due to their permanent skin integration, immunocompatibility, and their ability to retain the inherent structure of the skin [
3]. However, large and extensive wounds might become a problem for autografts, as the patient probably does not have enough available skin to harvest [
2,
4].
Allografts and xenografts are the options for skin grafting to large and extensive wounds. Both grafts are commonly used as a temporary wound coverage while awaiting more definitive skin closure treatment or for patients needing resuscitation before autografting. Although allografts have the ability to undergo revascularization, they are used temporarily due to immune rejection and infection [
3]. Allografts are more difficult to acquire and need to go through a long process before being able to be grafted to the patient to reduce the risk of contamination and transmitted disease [
2]. Xenografts do not have the ability to revascularize, thus making them a temporary wound closure to promote healing. They are used in the short term as they will not integrate with the recipient’s tissue [
3]. Bovine and porcine grafts are commonly used xenografts, although the use of fish grafts is rising due to the latest research that has shown them to be more beneficial. An ideal xenograft should be considered based on the strength, flexibility, adhesion to the wound, aesthetic result, and optimal wound healing. The safety of the graft should also be taken into consideration, such as the risk of disease transmission and rejection reactions. Bovine and porcine grafts need to go through a lengthy preservation process before being used to lower the risk of disease transmission. This lengthy process also often causes a large portion of collagen that could help with wound healing to be lost [
2,
4]. Meanwhile, fish skin grafts (FSGs) do not need to go through a lengthy preservation process, as they are considered to pose a lower risk of disease transmission compared to mammalian grafts [
1,
2]. An in vivo and in vitro study found that FSG collagen contents possessed good blood compatibility, had a higher cell viability than naturally derived biomaterials (T-1), and had a significantly lower immunological reaction compared to bovine tendons [
5]. Consistent with other types of xenografts, FSGs serve as a temporary wound dressing. Other wound dressings that are commonly used are collagen alginate dressings and silver sulfadiazine cream 1%. Both dressings require a lot of dressing changes, thus resulting in more high-maintenance wound care [
6].
Fish skin grafts may be harvested from Atlantic Cod or Nile Tilapia; both species live in different areas of the world, making FSGs more accessible worldwide. The preservation process of FSGs makes it possible to store them for up to 3 years at room temperature [
2]. The FSG is found to be more porous compared to dehydrated amnion/chorion membrane allograft (dHACM); fish skin contains 16.7 holes per 100 µm on average, whereas the dHACM contains 1.7 holes per 100 µm on average. The average diameter of the pores in the fish skin graft is 16.1 µm, and that of the pores in the dHACM is 1.3 µm [
7]. This allows more fibroblasts and keratinocytes to pass through, thus resulting in faster wound healing. Fish skins are rich in collagen (type 1 and 2), which are known to help in the third stage of wound healing. They also contain different fatty acids, which aid wound healing by affecting the production and activity of cytokines and competing with the inflammatory arachidonic acid to inhibit proinflammatory eicosanoid production. Among those fatty acids, omega-3 polyunsaturated fatty acid plays a huge role, including as an antibacterial agent that lasts for 48–72 h [
2,
8]. This is shown in a cytotoxicity assay, where it was found to have antimicrobial and anti-biofilm activity in vitro against
S. aureus,
S. epidermidis, and
P. aeruginosa, as well as against multidrug-resistant
S. aureus [
9]. Omega-3 fatty acid also promotes wound healing by helping tissue regeneration by supporting revascularization and growth in the third and fourth stages of the wound healing process. FSG applications are relatively simple; FSG only needs to be soaked in 0.9% saline solution before being ready to be grafted on the patient. It can also be meshed, and only needs stitches or a medical patch to be applied [
1]. The application of fish skin grafts has been seen in different cases in recent years, namely chronic diabetic foot ulcers, burns, chronic wounds, and even hidradenitis suppurativa [
1].
Given the potential of fish skin grafts, we conducted a systematic review to assess the efficacy of fish skin grafts as wound dressings. The aim of this systematic review was to assess how fish skin grafts perform in the healing process of chronic wounds, mainly evaluating the duration of wound healing. Other factors that might impact the outcome of wound healing, such as infection and allergic reactions, will also be mentioned if available in the articles included in this study.
2. Materials and Methods
2.1. Search Strategy
This systematic review was conducted in line with the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) guideline. PubMed, Cochrane, and ScienceDirect databases were explored in March 2024 using “fish skin graft AND wound graft AND acellular fish skin” as keywords, resulting a total of 460 results. Any type of research that used fish skin grafts as a treatment option in humans, was written in English, had full text available, and was published in the past 5 years was included in this study.
Figure 1 shows the PRISMA flow diagram indicating the study search and identification strategies.
2.2. Inclusion Criteria
This systematic review included original studies, such as randomized controlled trials, cohort studies, case series, and case reports, that met the other inclusion criteria. The other inclusion criteria were as follows: the research was published no more than five years ago, was performed on human subjects, and used fish skin grafts as a wound dressing, and the research objective was to find the efficacy of fish skin grafts.
2.3. Data Collection Process
The required data that were extracted from studies included in this research were independently extracted from every study by the authors using a standard data extraction format. Any identified discrepancies were resolved through discussion and consultation with experts. The data collected in each study were author(s), year of publication, study region, research design, sample characteristics, sample size, intervention, and outcomes.
2.4. Risk of Bias Assessment
A risk of bias assessment was conducted of all studies included in this systematic review using NIH study quality assessment tools. The quality assessment tools were used and adapted accordingly to accommodate all types of studies included in this systematic review. A total of 9 possible sources of bias were identified: research question (was the study question or objective clearly stated?); study population (were eligibility/selection criteria for the study prespecified and clearly described?); study representation (were the participants in the study representative of those who would be eligible for the intervention in the general or clinical population of interest?); participation (were all eligible participants that met the prespecified entry criteria enrolled?); sample size (was the sample size sufficiently large to provide confidence in findings?); intervention (was the intervention clearly described and delivered consistently across the study population?); outcome (were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants?); follow-up (was the loss to follow-up after baseline 20% or less, and were those lost to follow-up accounted for in the analysis?); and control of cofounders (were key potential confounding variables measured and statistically adjusted for their impact on the outcomes?).
Table 1 reports the summary of risk of bias evaluation of each study, with Y indicating yes, N indicating No, and N/A indicating the evaluation was not able to be performed for the study.
4. Discussion
Acellular fish skin as a xenograft promises a lot of benefits towards chronic wound healing, namely burns and diabetic foot ulcers. Other known xenografts are harvested from mammals, posing the risk of disease transmission, thus requiring harsh processing before being able to be grafted. Harsh processing removes components that may help in wound healing, such as lipids, glycans, elastin, hyaluronic acids, and soluble collagens [
1]. Out of the six studies that were reviewed, all studies show that FSG accelerates wound healing. Although all studies showed that FSG is efficacious towards wound healing, these studies were performed on different samples and varied demographics, one of which is the wound type that was treated. Lantis et al. [
11] and Michael et al. [
15] both treated diabetic foot ulcers, where Lantis found that the percentage of wounds healed after 12 weeks was increased in patients treated with FSG (56.9%) compared to those treated with collagen alginate therapy (31.4%). Michael et al. showed complete wound healing and wound size reduction of 87.57% from its initial size after 16 weeks [
15]. Reda et al. found early wound granulation in their study that was performed on full-thickness blast and burn injuries; this was found on the first follow-up, 7 days after grafting [
13]. Badois et al. concluded that healing time using FSG (mean = 31.5 days) was halved, compared to paraffin gauze (mean = 67.9 days). This study was conducted on a thin skin donor site, comparable to an intermediate or deep second-degree burn [
10]. The age groups were also varied between the studies; studies performed by Biazar et al. [
14] and Cherry et al. [
12] were carried out in pediatric patients, unlike other studies reviewed. Biazar et al. found complete wound healing in their study after 60 days on deep-thickness wounds treated with FSG [
14]. According to Cherry et al., complete re-epithelization using a fish skin graft took 29–62 days, with early wound granulation found only after a few days [
12]. Wound areas were halved after 30 days, according to Biazar et al. [
14]. Despite the variation in study designs, FSG shows promising, consistent results in promoting wound healing across different wound types and age groups.
These findings may be explained by the biological properties of fish skin grafts and the retention of structural and biochemical components such as type I collagen and omega-3 fatty acids after processing. Fiakos et al. analyzed FSG properties that may help in wound healing. It was found that fish skin has a similar structure to human skin, with both composed of three basic layers: epidermal, intermediate, and basal epithelial layers [
16]. This study also mentioned the porous structure of FSG, which allows ingrowth and attachment of human fibroblasts. It also highlights the high omega-3 content of FSG (19% of its overall lipid content) compared to mammalian grafts (0.5% of its lipid content) [
16]. While these components are hypothesized to support wound healing, the direct causal relationship between omega-3 content and improved clinical outcomes remains to be fully established. Seth et al. [
17] discussed the potential role of omega-3 fatty acids—specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—in modulating inflammation, enhancing the skin barrier, and providing antimicrobial effects. These fatty acids have been shown to influence the production of inflammatory cytokines such as IL-1β and IL-6. However, these mechanistic insights are primarily based on experimental or preclinical data, and further clinical studies are needed to confirm their contribution to wound healing when delivered via FSG.
Reports of adverse events associated with FSG are limited. Four studies—by Badois et al. [
10], Cherry et al. [
12], Reda et al. [
13], and Biazar et al. [
14]—explicitly noted that no infections or allergic reactions occurred in patients treated with FSG, although these findings were not supported by detailed safety monitoring protocols or definitions. Lantis et al. [
11] reported one infection in the FSG group, compared to five in the collagen alginate control group. While these observations suggest a favorable safety profile, the absence of systematic adverse event reporting across studies limits the strength of this conclusion. The potential antibacterial and anti-biofilm properties of omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—components retained in FSG—may contribute to infection control. These fatty acids have demonstrated in vitro efficacy against pathogens including Staphylococcus aureus (both MRSA and non-resistant strains), Vibrio vulnificus, and Candida albicans [
17]. However, the clinical relevance of these mechanisms in the context of FSG use remains to be validated in controlled trials. Several studies reported positive outcomes regarding scarring, pain, and cost when using fish skin grafts (FSGs), though the extent of quantitative assessment varies.
Cherry et al. [
12] noted satisfactory scar appearance in pediatric patients treated with FSG, including the absence of retraction and hypertrophic scars. However, the authors acknowledged the study’s reliance on subjective outcome measures and called for the use of standardized tools for pain and scar assessment to enhance data robustness. In contrast, Biazar et al. [
14] reported patient-reported pain scores between 1 and 4 out of 10, indicating a generally low pain experience, though no validated pain scale was used. Badois et al. [
10] applied the Visual Analog Scale (VAS) and observed a significant reduction in pain (VAS ≥ 3 at five days;
p = 0.0034). Lantis et al. [
11] was the only study to perform a cost-effectiveness analysis comparing fish skin grafts (FSGs) with collagen alginate therapy (CAT). While the cost per healed ulcer was higher for FSG than CAT in per-protocol analysis (USD 7364 vs. USD 3989), the annualized cost—accounting for ongoing treatment of nonhealing ulcers—favored FSG. Based on Medicare data and modeled outcomes, the total annual cost per patient was USD 13,926 for FSG compared to USD 16,744 for CAT, indicating a USD 2818 cost saving with FSG. These findings suggest that FSG may contribute to improved patient comfort and reduced treatment cost. However, more rigorous studies using validated pain assessment tools and structured cost-effectiveness evaluations are needed to support these observations.
There were several limitations in this study. Most studies reviewed in this study have a small sample size; therefore, studies with larger, well-designed randomized controlled trials with standardized outcome measures still need to be carried out. Another limitation was that there were not a lot of studies published that compared the efficacy of FSG and other wound dressings, especially the other grafts available. Further research around the use of fish skin grafts still needs to be explored. Despite these limitations, the available evidence suggests that FSG is a promising option for wound healing, particularly in complex or chronic wounds.
5. Conclusions
This study found that acellular fish skin grafts (FSGs) are a promising option for wound healing, particularly in chronic and complex wounds such as burns and diabetic foot ulcers. Across diverse patient populations and wound types, FSG has demonstrated consistent benefits in accelerating healing, reducing pain, and improving scar quality. Its favorable safety profile and the retention of bioactive components—such as type I collagen and omega-3 fatty acids—further support its therapeutic potential.
However, the strength of this evidence is limited by small sample sizes, lack of standardized outcome measures, and limited direct comparisons with other grafts or advanced wound dressings. Reports of adverse events and limited cost-effectiveness are inconsistent and often anecdotal. Therefore, large-scale, randomized controlled trials with rigorous clinical and safety evaluation are essential to establish the comparative effectiveness of FSG and guide its broader adoption in clinical practice.